192 related articles for article (PubMed ID: 22480142)
1. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus.
Rodgers MA; Villareal VA; Schaefer EA; Peng LF; Corey KE; Chung RT; Yang PL
J Am Chem Soc; 2012 Apr; 134(16):6896-9. PubMed ID: 22480142
[TBL] [Abstract][Full Text] [Related]
2. Desmosterol Increases Lipid Bilayer Fluidity during Hepatitis C Virus Infection.
Costello DA; Villareal VA; Yang PL
ACS Infect Dis; 2016 Nov; 2(11):852-862. PubMed ID: 27933788
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Selectively Alters the Intracellular Localization of Desmosterol.
Villareal VA; Fu D; Costello DA; Xie XS; Yang PL
ACS Chem Biol; 2016 Jul; 11(7):1827-33. PubMed ID: 27128812
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus NS3-4A protease regulates the lipid environment for RNA replication by cleaving host enzyme 24-dehydrocholesterol reductase.
Tallorin L; Villareal VA; Hsia CY; Rodgers MA; Burri DJ; Pfeil MP; Llopis PM; Lindenbach BD; Yang PL
J Biol Chem; 2020 Aug; 295(35):12426-12436. PubMed ID: 32641492
[TBL] [Abstract][Full Text] [Related]
5. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.
Blaising J; Pécheur EI
Biochimie; 2013 Jan; 95(1):96-102. PubMed ID: 22884392
[TBL] [Abstract][Full Text] [Related]
6. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.
Villareal VA; Rodgers MA; Costello DA; Yang PL
Antiviral Res; 2015 Dec; 124():110-21. PubMed ID: 26526588
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.
Shahidi M; Tay ESE; Read SA; Ramezani-Moghadam M; Chayama K; George J; Douglas MW
J Gen Virol; 2014 Nov; 95(Pt 11):2468-2479. PubMed ID: 25053565
[TBL] [Abstract][Full Text] [Related]
8. 2-octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated protein kinase.
Yang D; Xue B; Wang X; Yu X; Liu N; Gao Y; Liu C; Zhu H
PLoS One; 2013; 8(5):e64932. PubMed ID: 23741428
[TBL] [Abstract][Full Text] [Related]
9. Modulation of host metabolism as a target of new antivirals.
Ikeda M; Kato N
Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.
Park SB; Boyer A; Hu Z; Le D; Liang TJ
Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685
[TBL] [Abstract][Full Text] [Related]
11. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.
Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS
Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169
[TBL] [Abstract][Full Text] [Related]
12. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
13. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms.
Chen Y; Wang S; Yi Z; Tian H; Aliyari R; Li Y; Chen G; Liu P; Zhong J; Chen X; Du P; Su L; Qin FX; Deng H; Cheng G
Sci Rep; 2014 Dec; 4():7242. PubMed ID: 25467815
[TBL] [Abstract][Full Text] [Related]
14. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
[TBL] [Abstract][Full Text] [Related]
15. Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression.
Lin CK; Tseng CK; Liaw CC; Huang CY; Wei CK; Sheu JH; Lee JC
Sci Rep; 2018 Jun; 8(1):8676. PubMed ID: 29875371
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
[TBL] [Abstract][Full Text] [Related]
17. [Effects of telaprevir (TVR) on cholesterol metabolism].
Nakamuta M; Kohjima M
Nihon Rinsho; 2015 Dec; 73 Suppl 9():199-203. PubMed ID: 26845930
[No Abstract] [Full Text] [Related]
18. Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response.
Islam KU; Anwar S; Patel AA; Mirdad MT; Mirdad MT; Azmi MI; Ahmad T; Fatima Z; Iqbal J
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851679
[TBL] [Abstract][Full Text] [Related]
19. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy.
González-Aldaco K; Torres-Reyes LA; Ojeda-Granados C; José-Ábrego A; Fierro NA; Román S
Ann Hepatol; 2018 Oct; 17(6):908-919. PubMed ID: 30600305
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance.
Bang BR; Li M; Tsai KN; Aoyagi H; Lee SA; Machida K; Aizaki H; Jung JU; Ou JJ; Saito T
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
